4-phenylbutylamine has been researched along with Malignant Melanoma in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Eigner, K; Filik, Y; Hengstschläger, M; Klambauer, G; Mark, F; Mikula, M; Moriggl, R; Röhrl, C; Schütz, B; Stangl, H | 1 |
1 other study(ies) available for 4-phenylbutylamine and Malignant Melanoma
| Article | Year |
|---|---|
The unfolded protein response impacts melanoma progression by enhancing FGF expression and can be antagonized by a chemical chaperone.
Topics: Animals; Antineoplastic Agents; Biomarkers, Tumor; Butylamines; Cell Line, Tumor; Cell Movement; Cell Survival; Disease Progression; Endoplasmic Reticulum Stress; Fibroblast Growth Factors; Gene Expression Regulation, Neoplastic; Humans; Melanocytes; Melanoma; Mice; Mutation; Neoplasm Transplantation; Proto-Oncogene Proteins B-raf; Unfolded Protein Response | 2017 |